|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...3334353637383940414243...6768» |
- peripheral blood stem cell transplantation / National Cancer Institute
Trial termination: Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Jun 4, 2014
P2, N=48, Terminated, Sponsor: Columbia University
Recruiting --> Terminated; Poor enrollment
- peripheral blood stem cell transplantation / National Cancer Institute
Trial initiation date: Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Jun 4, 2014
P2, N=48, Terminated, Sponsor: Columbia University
Recruiting --> Terminated; Poor enrollment Initiation date: Jan 1997 --> Jul 1996
- Enrollment change: Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures (clinicaltrials.gov) - Jun 4, 2014
P3, N=0, Withdrawn, Sponsor: Massachusetts General Hospital
Initiation date: Jan 1997 --> Jul 1996 N=1300 --> 0
- peripheral blood stem cell transplantation / National Cancer Institute
Enrollment change: Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Jun 4, 2014
P2, N=48, Terminated, Sponsor: Columbia University
N=1300 --> 0 N=62 --> 48
- Trial primary completion date, Combination therapy: Combination Study of Revlimid (clinicaltrials.gov) - Jun 4, 2014
P1/2, N=78, Active, not recruiting, Sponsor: Moshe Talpaz, M.D.
N=62 --> 48 Trial primary completion date: Oct 2013 --> Jan 2017
- | lenalidomide / Generic mfg.
Biomarker, Enrollment change: Lenalidomide Maintenance Therapy for Multiple Myeloma (clinicaltrials.gov) - Jun 3, 2014
P2, N=11, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2013 --> Jan 2017 N=28 --> 11
- | lenalidomide / Generic mfg.
Biomarker, Enrollment closed: Lenalidomide Maintenance Therapy for Multiple Myeloma (clinicaltrials.gov) - Jun 3, 2014
P2, N=11, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=28 --> 11 Recruiting --> Active, not recruiting
- dasatinib / Generic mfg.
Enrollment closed, Surgery, Metastases: S0711: Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 2, 2014
P1, N=42, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| lenalidomide / Generic mfg., thalidomide / Generic mfg., pomalidomide / Generic mfg.
Clinical: Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma (clinicaltrials.gov) - Jun 2, 2014
P3, N=172, Not yet recruiting, Sponsor: Celgene Corporation
- |||| Nplate (romiplostim) / Amgen, Kyowa Kirin
Trial primary completion date: Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients (clinicaltrials.gov) - Jun 1, 2014
P3, N=60, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2015 --> Oct 2015
- dinaciclib (MK-7965) / Merck (MSD)
Trial completion: Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 1, 2014
P2, N=29, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2015 --> Oct 2015 Active, not recruiting --> Completed
- PVX-410 / OncoPep
Trial primary completion date: Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma (clinicaltrials.gov) - May 29, 2014
P1/2, N=22, Recruiting, Sponsor: OncoPep, Inc.
Active, not recruiting --> Completed Trial primary completion date: Sep 2014 --> Mar 2015
- || Ojjaara (momelotinib) / GSK
Trial primary completion date, IO biomarker: Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (clinicaltrials.gov) - May 29, 2014
P1/2, N=61, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Sep 2014 --> Mar 2015 Trial primary completion date: Dec 2013 --> Jun 2014
- | PVX-410 / OncoPep
Enrollment change: Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma (clinicaltrials.gov) - May 29, 2014
P1/2, N=22, Recruiting, Sponsor: OncoPep, Inc.
Trial primary completion date: Dec 2013 --> Jun 2014 N=13 --> 22
- | dexamethasone / Generic mfg.
New P2 trial: An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - May 29, 2014
P2, N=60, Recruiting, Sponsor: Shandong University
- || afuresertib (LAE002) / Laekna Therap
Trial primary completion date, Combination therapy: Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma (clinicaltrials.gov) - May 28, 2014
P1, N=90, Active, not recruiting, Sponsor: GlaxoSmithKline
N=13 --> 22 Trial primary completion date: Sep 2013 --> Dec 2014
- Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date: Study of Natalizumab in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - May 28, 2014
P1/2, N=6, Terminated, Sponsor: Biogen Idec
Trial primary completion date: Sep 2013 --> Dec 2014 Trial primary completion date: Nov 2010 --> Dec 2009
- Tysabri (natalizumab) / Biogen, Royalty
Trial initiation date: Study of Natalizumab in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - May 28, 2014
P1/2, N=6, Terminated, Sponsor: Biogen Idec
Trial primary completion date: Nov 2010 --> Dec 2009 Initiation date: May 2008 --> Sep 2008
- doxycycline / Generic mfg.
Enrollment open: A Phase II Study of Doxycycline in Relapsed NHL (clinicaltrials.gov) - May 28, 2014
P2, N=20, Recruiting, Sponsor: University of Rochester
Initiation date: May 2008 --> Sep 2008 Not yet recruiting --> Recruiting
- || afuresertib (LAE002) / Laekna Therap
Enrollment closed, Combination therapy: Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma (clinicaltrials.gov) - May 28, 2014
P1, N=90, Active, not recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Trial primary completion date: Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) (clinicaltrials.gov) - May 28, 2014
P1, N=52, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2014 --> Jan 2015
- | Trial completion date: Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) (clinicaltrials.gov) - May 28, 2014
P1, N=52, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Sep 2014 --> Jan 2015 Trial completion date: Sep 2014 --> Jan 2015
- || afuresertib (LAE002) / Laekna Therap
Trial initiation date, Combination therapy: Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma (clinicaltrials.gov) - May 28, 2014
P1, N=90, Recruiting, Sponsor: GlaxoSmithKline
Trial completion date: Sep 2014 --> Jan 2015 Initiation date: Dec 2011 --> Mar 2012
- Trial suspension: Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant (clinicaltrials.gov) - May 27, 2014
P2, N=70, Suspended, Sponsor: Greg Monohan
Initiation date: Dec 2011 --> Mar 2012 Recruiting --> Suspended
- || BeneFix (nonacog alfa) / Pfizer
Trial completion: Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B (clinicaltrials.gov) - May 27, 2014
P3, N=25, Completed, Sponsor: Pfizer
Recruiting --> Suspended Active, not recruiting --> Completed
- ||| dexamethasone / Generic mfg., pomalidomide / Generic mfg.
Clinical: CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis (clinicaltrials.gov) - May 27, 2014
P2, N=378, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed N=258 --> 378
- | Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Trial primary completion date: Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia (clinicaltrials.gov) - May 27, 2014
P3, N=40, Completed, Sponsor: Octapharma
N=258 --> 378 Trial primary completion date: Oct 2014 --> Jul 2013
- Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Trial completion date: Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia (clinicaltrials.gov) - May 27, 2014
P3, N=40, Completed, Sponsor: Octapharma
Trial primary completion date: Oct 2014 --> Jul 2013 Trial completion date: Dec 2014 --> Feb 2014
- | Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Enrollment change: Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia (clinicaltrials.gov) - May 27, 2014
P3, N=40, Completed, Sponsor: Octapharma
Trial completion date: Dec 2014 --> Feb 2014 N=95 --> 40
- || Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
Trial completion: Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia (clinicaltrials.gov) - May 27, 2014
P3, N=40, Completed, Sponsor: Octapharma
N=95 --> 40 Recruiting --> Completed
- armodafinil / Generic mfg.
Trial completion date: A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma (clinicaltrials.gov) - May 26, 2014
P3, N=50, Completed, Sponsor: Oncotherapeutics
Recruiting --> Completed Trial completion date: Sep 2013 --> May 2014
- Gammaplex (intravenous normal human immunoglobulin) / Bio Products Lab
Trial completion: A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency (clinicaltrials.gov) - May 26, 2014
P4, N=25, Completed, Sponsor: Bio Products Laboratory
Trial completion date: Sep 2013 --> May 2014 Active, not recruiting --> Completed
- || armodafinil / Generic mfg.
Trial completion: A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma (clinicaltrials.gov) - May 26, 2014
P3, N=50, Completed, Sponsor: Oncotherapeutics
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Genasense (oblimersen) / Genta, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - May 26, 2014
P2, N=48, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Trial primary completion date, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - May 26, 2014
P1, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Jun 2014 --> Apr 2015
- Empliciti (elotuzumab) / AbbVie, BMS
Trial completion date, Combination therapy: Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - May 26, 2014
P2, N=40, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jun 2014 --> Apr 2015 Trial completion date: Jun 2014 --> Jun 2015
- melphalan / Generic mfg., carfilzomib / Generic mfg., bendamustine / Generic mfg.
P1 data: Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma (clinicaltrials.gov) - May 26, 2014
P1, N=26, Recruiting, Sponsor: Spectrum Health Hospitals
- Yervoy (ipilimumab) / BMS
Trial termination, IO biomarker: MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma (clinicaltrials.gov) - May 21, 2014
P1/2, N=18, Terminated, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2014 --> Jun 2015 Completed --> Terminated
- cyclophosphamide / Generic mfg., carfilzomib / Generic mfg.
Clinical: A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma (clinicaltrials.gov) - May 21, 2014
P1, N=38, Recruiting, Sponsor: Academic Myeloma Consortium
Completed --> Terminated Trial primary completion date: Sep 2013 --> Nov 2014
- marzeptacog alfa (CB 813d) / GC Biopharma
Trial primary completion date: Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia (clinicaltrials.gov) - May 21, 2014
P1, N=24, Recruiting, Sponsor: Pfizer
Trial primary completion date: Sep 2013 --> Nov 2014 Trial primary completion date: Apr 2014 --> Oct 2014
- ||||| Tavalisse (fostamatinib) / Rigel
Trial initiation date: A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - May 21, 2014
P3, N=75, Recruiting, Sponsor: Rigel Pharmaceuticals
Trial primary completion date: Apr 2014 --> Oct 2014 Initiation date: Apr 2014 --> May 2014
- cyclophosphamide / Generic mfg., carfilzomib / Generic mfg.
Clinical: A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma (clinicaltrials.gov) - May 21, 2014
P1, N=38, Recruiting, Sponsor: Academic Myeloma Consortium
Initiation date: Apr 2014 --> May 2014 Trial completion date: Sep 2014 --> Mar 2015
- marzeptacog alfa (CB 813d) / GC Biopharma
Trial completion date: Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia (clinicaltrials.gov) - May 21, 2014
P1, N=24, Recruiting, Sponsor: Pfizer
Trial completion date: Sep 2014 --> Mar 2015 Trial completion date: Apr 2014 --> Oct 2014
- || New P2/3 trial: GERMAIN: Treatment Optimization in Patients With Untreated Multiple Myeloma (clinicaltrials.gov) - May 21, 2014
P2/3, N=290, Recruiting, Sponsor: Lars-Olof Muegge
- |||||| Tavalisse (fostamatinib) / Rigel
Enrollment open: A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - May 21, 2014
P3, N=75, Recruiting, Sponsor: Rigel Pharmaceuticals
Trial completion date: Apr 2014 --> Oct 2014 Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / BMS
Enrollment change, IO biomarker: MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma (clinicaltrials.gov) - May 21, 2014
P1/2, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=18 --> 36
- |||| bortezomib / Generic mfg.
Trial completion: Velcade Consolidation Bone Study (clinicaltrials.gov) - May 20, 2014
P2, N=106, Completed, Sponsor: Janssen-Cilag International NV
N=18 --> 36 Active, not recruiting --> Completed
- OPB-51602 / Otsuka
Trial primary completion date: Phase I Study of OPB-51602 in Patients With Hematologic Malignancies (clinicaltrials.gov) - May 20, 2014
P1, N=20, Completed, Sponsor: Otsuka Pharmaceutical Co., Ltd.
Active, not recruiting --> Completed Trial primary completion date: Dec 2013 --> Apr 2014
- OPB-51602 / Otsuka
Trial completion date: Phase I Study of OPB-51602 in Patients With Hematologic Malignancies (clinicaltrials.gov) - May 20, 2014
P1, N=20, Completed, Sponsor: Otsuka Pharmaceutical Co., Ltd.
Trial primary completion date: Dec 2013 --> Apr 2014 Trial completion date: Dec 2013 --> Apr 2014
- | OPB-51602 / Otsuka
Trial completion: Phase I Study of OPB-51602 in Patients With Hematologic Malignancies (clinicaltrials.gov) - May 20, 2014
P1, N=20, Completed, Sponsor: Otsuka Pharmaceutical Co., Ltd.
Trial completion date: Dec 2013 --> Apr 2014 Recruiting --> Completed